Back to Search Start Over

Global epidemiology of HBV infection among hemodialysis patients: A systematic review and meta-analysis.

Authors :
Khalesi Z
Razizadeh MH
Javadi M
Bahavar A
Keyvanlou Z
Saadati H
Letafati A
Khatami A
Kachooei A
Khales P
Alborzi E
Hosseini M
Tambrchi V
Jafari Maskouni E
Taheri N
Zafarani A
Motlaghzadeh S
Dehghani H
Shalpoush N
Masoudi A
Noorafza M
Habib Z
Zarei M
Kiani SJ
Ghorbani S
Source :
Microbial pathogenesis [Microb Pathog] 2023 Jun; Vol. 179, pp. 106080. Date of Electronic Publication: 2023 Mar 21.
Publication Year :
2023

Abstract

Background & Aims: Hemodialysis (HD) is a life-saving procedure that purifies the blood in patients with end-stage renal disease (ESRD). Among all major complications, blood-borne diseases like hepatitis B virus (HBV) may be exposed as serious side effects of hemodialysis. A comprehensive review of the global burden of HBV among HD patients has not been written so far. The aim of the current systematic review and meta-analysis was to determine the globally epidemiology of HBV infection among HD patients.<br />Methods: Based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, articles that investigated the prevalence of HBV among HD patients were searched from the major databases such as EMBASE, PubMed, Web of Science collection, and Scopus. Pooled prevalence with 95% CI and identification of heterogeneity were obtained using the random effects model and Cochran's Q-test, respectively, and quantification was evaluated using the I2 statistics. All statistical analyses were performed by STATA 14.1 statistical software.<br />Results: among 322 datasets (795,623 cases) that included in this study, the pooled prevalence of HBV infection among HD patients was 7.32% (95% CI: 6.53-8.15%; I2 = 97.91%), including 7.57% (95% CI: 6.69-8.48%) for HBsAg and 6.09% (95% CI: 4.05-8.49%) for DNA, respectively. In addition, based on geographic area, the prevalence was 7.44% (95% CI: 6.35-8.61%) in Asia, 4.32% (95% CI: 2.21-7.04%) in North America, 7.07% (95% CI: 6.35-8.61%) in Europe, 5.52% (95% CI: 3.60-7.78%) in Africa, 8.45% (95% CI: 5.81-11.78%) in Oceania, and 9.73% (95% CI: 7.11-12.70%) in South America.<br />Conclusions: Our analysis indicates a relatively high prevalence of HBV infection in HD patients, even in some developed countries. Considering that ESRD patients are not able to properly respond to the vaccination strategies in order to develop an acceptable immunity, vaccination of healthy individuals is highly recommended to arm their bodies for possible immunocompromise conditions in the future. Moreover, donated blood in blood transfusion centers should be checked for possible hepatitis B virus infection using sensitive molecular tests.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2023 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1096-1208
Volume :
179
Database :
MEDLINE
Journal :
Microbial pathogenesis
Publication Type :
Academic Journal
Accession number :
36948364
Full Text :
https://doi.org/10.1016/j.micpath.2023.106080